A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer.
Antonio GiordanoPriya U KumthekarQingchun JinBusem Binboğa KurtSiyang RenTianyu LiJosé Pablo LeoneElizabeth A MittendorfAlyssa M PeresleteLaura SharpRaechel DavisMolly DiLulloNabihah TayobErica L MayerEric P WinerSara M TolaneyNancy U LinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The addition of atezolizumab to pertuzumab plus high-dose trastuzumab does not result in improved CNS responses in patients with HER2-positive breast cancer brain metastases.
Keyphrases
- positive breast cancer
- high dose
- epidermal growth factor receptor
- phase ii study
- brain metastases
- metastatic breast cancer
- small cell lung cancer
- stem cell transplantation
- low dose
- tyrosine kinase
- open label
- locally advanced
- placebo controlled
- cerebrospinal fluid
- rectal cancer
- squamous cell carcinoma
- clinical trial